After a long road filled with scrutiny and uncertainty, Amylyx’s amyotrophic lateral sclerosis (ALS) drug,…Read More
A Phase 3 clinical trial of the investigational drug tofersen in patients with MND caused…Read More
Interesting findings from Kay Double and Benjamin Trist at the University of Sydney – the…Read More
Biogen is seeking approval of tofersen under the FDA’s accelerated approval pathway, based on the…Read More
Albrioza, also known as AMX0035, has been approved by Health Canada subject to conditions, including…Read More
Tofersen, has been designed to work by stopping the production of abnormal SOD1 protein that…Read More
Topline results from the Phase 2a trial of Tegoprubart have been announced, showing the drug…Read More
On May 12, the US Food and Drug Administration (FDA) granted approval to oral edaravone…Read More
With a burst of activity in recent months, the pipeline of development for ALS/MND has…Read More
If you are interested in learning more about CRISPR read this blog by MND Association…Read More
Wave Life Sciences announces a positive update to the ongoing phase 1b/2a FOCUS-C9 Study which…Read More
Signs of dementia can be treated if they’re found early enough, but early detection is…Read More
Researchers at King’s College London led by New Zealander Professor Christopher Shaw, are the first…Read More
A new machine learning algorithm to measure ALS/MND symptom severity has been developed by Google…Read More
Dr Scotter and Dr Swanson from the University of Auckland in collaboration with researchers at…Read More
Biogen has expanded eligibility for its early access program (EAP) for the investigational therapy tofersen. …Read More
An international collaboration led by Flinders University identified a potential biomarker for ALS/MND, providing a…Read More
Scientists at the Medical Research Council Laboratory for Molecular Biology in Cambridge, UK have determined…Read More
Researchers at Trinity College Dublin, have found that MND has 4 distinct patterns of changes…Read More
Two investigational small molecule therapeutics have reported positive phase 1 clinical results, as well as…Read More